Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Revenue projections:

Revenue projections for NATCOPHARM
Revenue projections for NATCOPHARM

NATCO Pharma Limited's revenue is projected to decrease from last year, a development that could lead investors to adopt a more cautious approach. A revenue decline can negatively affect profitability, signaling challenges for the company and making it less attractive for those seeking solid financial performance.

Financial Ratios:

currentRatio 0.000000
forwardPE 29.411339
debtToEquity 3.012000
earningsGrowth 0.139000
revenueGrowth 0.363000
grossMargins 0.819710
operatingMargins 0.173800
trailingEps 86.930000
forwardEps 39.977780

NATCOPHARM's Forward PE is within a good range, showing that the stock price compares well to its earnings. This suggests it isn't overpriced and leaves room for growth, making the stock appealing to investors looking for value and growth opportunities.
NATCOPHARM's positive earnings and revenue growth suggest that the company is expected to expand its business. This reflects a healthy financial outlook, as NATCOPHARM's increasing profits and sales signal further growth in the near future.
NATCOPHARM's forward EPS being less than trailing EPS indicates the company's profitability is expected to decrease. This signals a potential downturn in financial performance compared to the previous year.

Price projections:

Price projections for NATCOPHARM
Price projections for NATCOPHARM

Over time, NATCOPHARM's price projections have been consistently revised lower. This suggests analysts are becoming less optimistic about the company's future prospects and are adjusting their forecasts accordingly.

The price of NATCOPHARM has surpassed the higher end of projections, indicating impressive growth. However, the lack of room for further upward movement may suggest that investors should prepare for potential price adjustments.

Insider Transactions:

Insider Transactions for NATCOPHARM
Insider Transactions for NATCOPHARM


6 transactions to sell NATCOPHARM occurred, with market price at 893.3249918619791.There were 2 buy transactions of NATCOPHARM, with market price at 851.625.The transactions conducted by insiders do not indicate any significant pattern, leaving little to infer about the company’s strategic moves.

Recommendation changes over time:

Recommendations trend for NATCOPHARM
Recommendations trend for NATCOPHARM


With analysts showing a buy bias for NATCOPHARM, investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, positioning NATCOPHARM as a safe and profitable place for investors to allocate their funds and seek growth.